{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"], "versionId": "66", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "236553", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313880"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85789"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73212"}], "name": "End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880", "title": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparatorOnlyEvidence", "display": "ComparatorOnlyEvidence"}]}}], "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "note": [{"text": "Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/)."}], "variableDefinition": [{"description": "Adults with type 2 diabetes with moderate CV risk -- Standard care", "variableRole": "population", "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85390-C-85789", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Standard care Group in Adults with type 2 diabetes with moderate CV risk", "reference": "Group/236534"}}, {"description": "End-stage kidney disease", "variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313880", "assigner": {"display": "Computable Publishing LLC"}}, "display": "End-stage kidney disease", "reference": "EvidenceVariable/236551"}}], "synthesisType": [{"text": "NOTSET"}], "studyDesign": [{"text": "NO_STUDY"}], "statistic": [{"description": "Risk 2.0%", "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000607", "display": "proportion"}]}, "quantity": {"value": 0.02}}], "url": "https://fevir.net/resources/Evidence/236553", "id": "236553", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "citeAs": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236553. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236553. Computable resource at: https://fevir.net/resources/Evidence/236553#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}